Dtsch Med Wochenschr 2009; 134(15): 759-762
DOI: 10.1055/s-0029-1220227
Prinzip & Perspektive | Review article
Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Direkte Renininhibition: ein neues und viel versprechendes Wirkprinzip in der Herzinsuffizienztherapie?

Direct renin inhibition: a new and promising treatment principle in heart failure?F. Mahfoud1 , C. Ukena1 , M. Böhm1
  • 1Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar
Further Information

Publication History

eingereicht: 26.11.2008

akzeptiert: 15.1.2009

Publication Date:
01 April 2009 (online)

Literatur

  • 1 Alderman M H, Madhavan S, Ooi W L, Cohen H, Sealey J E, Laragh J H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.  N Engl J Med. 1991;  324 1098-1104
  • 2 Brown M J. Aliskiren.  Circulation. 2008;  118 773-784
  • 3 Burnier M, Brunner H R. Angiotensin II receptor antagonists.  Lancet. 2000;  355 637-645
  • 4 Mueller D N, Luft F C. Renin receptor blockade: a better strategy for renal protection than Renin-Angiotensin system inhibition?.  Current Hypertension Rep. 2008;  10 405-409
  • 5 Latini R, Masson S, Anand I. et al . The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.  Eur Heart J. 2004;  25 292-299
  • 6 Luft F C. Renin and its putative receptor remain enigmas.  J Am Soc Nephrol. 2007;  18 1989-1892
  • 7 McMurray J, Bertram P, Latini R. et al . Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.  Circulation Heart Failure. 2008;  1 17-24
  • 8 Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer J D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.  J Clin Invest. 2002;  109 1417-1427
  • 9 Parving H H, Persson F, Lewis J B, Lewis E J, Hollenberg N K. Aliskiren combined with losartan in type 2 diabetes and nephropathy.  N Engl J Med. 2008;  358 2433-2446
  • 10 Parving H H, Lewis J B, Lewis E J, Hollenberg N K. AVOID Aliskiren in the Evaluation of Proteinuria in Diabetes. California, USA; American Society of Nephrology Renal Week Congress in San Francisco 2007 Poster SA-P01051
  • 11 Pfeffer M A, McMurray J J, Velazquez E J. et al . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.  N Engl J Med. 2003;  349 1893-1906
  • 12 Skeggs L T, Kahn J R, Lentz K, Shumway N P. The preparation, purification, and amino acid sequence of a polypeptide renin substrate.  J Exp Med. 1957;  106 439-453
  • 13 Solomen S D, Appelbaum E, Manning W. et al . Effect o fthe direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.  Circulation. 2009;  119 530-537
  • 14 Staessen J A, Li Y, Richart T. Oral renin inhibitors.  Lancet. 2006;  368 1449-1456
  • 15 Werner C, Baumhakel M, Teo K K. et al . RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.  Clin Res Cardiol. 2008;  97 418-431

Dr. med. Felix Mahfoud

Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin

Kirrberger Straße

66421 Homburg/Saar

Phone: 06841/16-23000

Fax: 06841/16-23389

Email: felix.mahfoud@uks.eu

    >